Table 3.5.
Human leukocyte differentiation antigens
| CD | Alternative name | HLDA section | Ligand/receptor/substrate/associated molecule | Description and function | MW (kDa) | T cell | B cell | Dendritic cell | NK cell | Stem cell/precursor | Macrophage/monocyte | Granulocyte | Platelet | Erythrocyte | Endothelial cell | Epithelial cell | Gene locus | CD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD1a | R4 | T | Non-peptide antigen presenting molecules; involved in lymphocyte activation; related to thymic T cell development | 49/- | ⊕ | ⊕ | — | ⊕ | — | — | — | 1q22-q23 | CD1a | |||||
| CD1b | R1 | T | Non-peptide antigen presenting molecules; involved in lymphocyte activation; related to thymic T cell development | 45/- | ⊕ | ⊕ | — | ⊕ | − | − | − | 1q22-q23 | CD1b | |||||
| CD1c | M241, R7 | T | Non-peptide antigen presenting molecules; involved in lymphocyte activation; related to thymic T cell development. Expressed by a subset of peripheral blood B cells | 43/- | ⊕ | + | − | ⊕ | − | − | − | 1q22-q23 | CD1c | |||||
| CD1d | R3 | T | Non-peptide antigen presenting molecules; involved in lymphocyte activation; related to thymic T cell development | ⊕ | + | − | − | − | − | +c | 1q22-q23 | CD1d | ||||||
| CD1e | R4 | T | Non-peptide antigen presenting molecules; involved in lymphocyte activation; related to thymic T cell development | − | − | − | − | 1q22-q23 | CD1e | |||||||||
| CD2 | E-rosette R T11, LFA-2 | T | Receptor for CD58, CD48, CD59 and CD15; adhesion and signal-transducing molecule | 50/- | + | + | − | − | − | 1p13 | CD2 | |||||||
| CD3 | T3 | T | Associated with T cell receptor α/β or γ/δ dimer, signal transduction; assembly and expression of the T cell receptor complex | 20–26 | + | − | − | − | − | − | − | − | − | − | 11q23 | CD3 | ||
| CD4 | L3T4, W3/25 | T | MHC Class II, gp120, IL-16 | Co-receptor in antigen-induced T cell activation; thymic differentiation; regulation of T-B cell adhesion; primary receptor for HIV; binds to MHC class II. Also expressed in peripheral blood monocytes, tissue macrophages, granulocytes | 55 | + | − | − | − | + | − | − | − | − | − | 12pter-p12 | CD4 | |
| CD5 | T1, Tp67, Leu-1 | T | CD72, BCR, gp35–37 | Co-stimulatory molecule; receptor for constitutive (CD72) and inducible (gp35-37) B cell-specific molecules | 58/67 | + | + | − | − | − | − | − | 11q13 | CD5 | ||||
| CD6 | T12 | T | CD166 | Adhesion molecule. In thymocyte resistance to apoptosis and in positive selection; important in T mature cell response to both alloantigen and self-antigen | -/105–130 | + | + | − | − | − | − | 11q13 | CD6 | |||||
| CD7 | gp40 | T | Possible co-activation/adhesion modulating molecule | 40 | + | − | + | + | − | − | − | − | 17q25.2-q25.3 | CD7 | ||||
| CD8α | Leu2, T8 | T | MHC I, Lck | Co-receptor molecule; binds to MHC class I | 68/30–34 | + | − | + | − | − | − | − | − | − | − | 2p12 | CD8 α | |
| CD8β | CD8, Leu2, Lyt3 | T | Co-receptor molecule; binds to MHC class I | + | − | − | − | − | − | − | − | − | − | 2p12 | CD8β | |||
| CD9 | p24, DRAP-1, MRP-1 | Platelet | CD63, CD81, CD82 | Modulates cell adhesion and migration; triggers platelet activation; expressed on eosinophils and basophils | -/24,26 | ⊕ | + | − | + | + | + | + | + | 2p13 | CD9 | |||
| CD10 | CALLA, NEP, gp100 | B | Zinc metalloprotease; neutral endopeptidase; regulator of B cell growth and proliferation by hydrolysis of peptides with proliferative/anti-proliferative effects | 100/- | − | − | − | + | − | − | − | − | + | 3q25.1-q25.2 | CD10 | |||
| CD11a | LFA-1a Integrin αL | Adhesion structure | ICAM-1,2,3 | Intracellular adhesion and co-stimulation; binds to ICAM-1, ICAM-2, ICAM-3; expressed on eosinophils and basophils | 170/180 | + | + | + | + | + | − | − | 16p11.2 | CD11a | ||||
| CD11b | Integrin αM MAC-1a | Adhesion structure | iC3b,Fibrinogen | Adherence of polymorphonuclear neutrophils and monocytes to fibrinogen, ICAM-1 endothelium; extravasation; chemotaxis; apoptosis | 165/170 | + | + | + | + | + | + | − | − | 16p11.2 | CD11b | |||
| CD11c | Integrin αX, p150:95a | Adhesion structure | iC3b | Adherence of polymorphonuclear neutrophilis and monocytes to fibrinogen, ICAM-1 endothelium; binds iC3b-coated particles | 145/150 | + | + | + | + | + | + | − | − | 16p11.2 | CD11c | |||
| CDw12 | P90–120 | Myeloid | Function unknown | 150–160/120 | − | − | + | − | + | + | − | − | CDw12 | |||||
| CD13 | APN, Gp150 | Myeloid | Acts as receptor for coronavirus which causes upper respiratory tract infections; involved in interactions between human CMV and target cells; CD13 auto-Ab associated with GVHD | 150/- | − | − | − | + | + | + | − | − | + | + | 15q25-q26 | CD13 | ||
| CD14 | LPS-R | Myeloid | LPS | Receptor for lipopolysaccharide (endotoxin) | 53/55 | − | − | − | + | + | 5q31.1 | CD14 | ||||||
| CD15 | X-hapten, Lewis X | Carbohydrate | CD62 selectin | May be important for direct carbohydrate-carbohydrate interactions | − | − | − | − | + | + | − | − | − | CD15 | ||||
| CD15s | Sialyl Lewis X | Carbohydrate and lectin | E-selectins | Expressed on myelomonocytic leukemia, some lyphocytic leukemia cells, and on adenocarcinomas | + | ⊕ | + | + | + | + | CD15s | |||||||
| CD15 u | 3′ sulpho Lewis X | Carbohydrate and lectin | P-selectins | CD15 subgroups involved with different carbohydrate to carbohydrate cell adhesion | + | ⊕ | + | + | + | − | + | CD15u | ||||||
| CD15su | 6 sulphosialyl Lewis X | Carbohydrate and lectin | L-selectins | CD15 subgroups involved with different carbohydrate to carbohydrate cell adhesion | + | ⊕ | + | + | + | − | + | CD15su | ||||||
| CD16 | FcγRIIIa | NK | Fc | Low affinity receptor for IgG. Major histocompatibility complex | 50–65/- | − | − | + | + | + | + | − | − | CD16 | ||||
| CD16b | FcγRIIIb | NK | Fc | Function unknown | N/A | + | + | + | + | − | − | + | CD16b | |||||
| CDw17 | None | Myeloid | Possible role in phagocytosis. Expressed in basophils | 150–160/120 | + | + | + | − | + | + | + | − | + | + | CDw17 | |||
| CD18 | Integrin β2 | Adhesion structure | CD11a, b, c | Leukocyte adhesion | 90/95 | + | + | + | + | + | − | − | 21q22.3 | CD18 | ||||
| CD19 | B4 | B | CD2, CD81, CD225 | A critical signal transduction molecule that regulates B cell development, activation and differentiation | 90 | − | + | + | − | + | − | − | − | − | − | − | 16p11.2 | CD19 |
| CD20 | B1, Bp35 | B | Regulation of B cell activation and proliferation by regulating transmembrane Ca2+ conductance and cell cycle progression | 37/35 | − | + | − | − | − | − | − | − | − | − | − | 11q12-q13.1 | CD20 | |
| CD21 | CR2, EBV-R, C3dR | B | C3d, CD23, CD19, CD81 | Receptor for EBV and C3d, C3dg, and iC3b; subset of immature thymocytes; CD21 is part of a large signal transduction complex that also involves CD91, CD81, and Leu1 | 130–145 | − | + | − | − | + | − | − | − | − | − | + | 1q32 | CD21 |
| CD22 | BL-CAM, Lyb8 | B | p72sky, p53/56lyn, SHP1 | Adhesion molecule; signaling molecule; antibody treatment of leukemia and lymphoma | 135 | − | + | − | − | + | − | − | − | − | − | − | 19p13.1 | CD22 |
| CD23 | Fc⊕RII, B6, BLAST-2 | B | IgE, CD21, CD11b, CD11c | Low affinity IgE receptor; regulates IgE synthesis; triggers monokine release; serum soluble CD23 level is a significant prognostic marker in CLL | 50–45 | − | + | − | − | − | − | − | 19p13.3 | CD23 | ||||
| CD24 | BBA-1, HSA | B | P-selectin | Function unknown; homologous to mouse heat stable antigen; P-selectin on human carcinomas is involved in carcinoma binding to platelets | 41/38 | − | + | − | − | − | − | + | − | − | − | + | 6g21 | CD24 |
| CD25 | Tac antigen, IL-2Rα | CK/CKR | IL-2 | IL-2 receptor α chain; associated with CD122 and CD132 | 55 | ⊕ | + | − | + | − | − | − | − | − | − | − | 10p15-p14 | CD25 |
| CD26 | DPP IV ectoenemye | T | Adenosine deaminase | Co-stimulatory molecule in T cell activation; associated marker of autoimmune diseases, adenosine deaminase-deficiency and HIV pathogenesis | 120 | + | + | − | + | − | − | − | − | − | − | + | 2q24.3 | CD26 |
| CD27 | T14, S152 | T | CD70, TRAF5, TRAF2 | Mediates a co-stimulatory signal for T cell activation. Involved in murine T cell development | 110–120 | + | + | − | + | − | − | − | − | − | − | − | 12p13 | CD27 |
| CD28 | Tp44, T44 | T | CD80, CD86 | Co-stimulates T cell proliferation and cytokine production with CD3; co-stimulates T cell effector function and T cell-dependent antibody production | 90 | + | − | − | − | − | − | − | − | − | − | − | 2q33 | CD28 |
| CD29 | Platelet GPIIa, β-1 integrin | Adhesion structure | VCAM-1 and MAdCAM-1 | Critical molecule for embryogenesis and development; essential to the differentiation of hematopoietic stem cells; associated with tumor progression and metastasis/invasion | 110130 | + | + | + | + | + | + | + | + | 10p11.2 | CD29 | |||
| CD30 | Ber-H2, Ki-1 | Non-lineage | CD153, TRAF1,2,3,5 | Member of TNFR family, involved in negative selection of T cells in thymus and TCR-mediated cell death; expressed on R-5 cells in Hodgkin's lymphomas | 120 | ⊕ | ⊕ | ⊕ | − | − | − | − | − | − | 1p36 | CD30 | ||
| CD31 | PECAM-1, endocam | Adhesion structure | CD38 | Adhesion receptor with signaling function that participates in an adhesion cascade; transendothelial migration cell-cell adhesion | 130–140 | + | + | + | + | + | + | − | + | 17q23 | CD31 | |||
| CD32 | FCγRII | Non-lineage | Phosphatases | Regulates B cell functions; major player in immune complex-induced tissue damage | 40 | − | + | − | + | + | + | − | − | 1q23 | CD32 | |||
| CD33 | P67 | Myeloid | Sugar chains | Diagnosis of acute myelogenous leukemia; negative selection for human self-regenerating hematopoietic stern cells | 67 | − | − | − | + | + | + | − | − | − | − | 19q13.3 | CD33 | |
| CD34 | gp 105–120 | Adhesion structure | L-selectin | Cell adhesion; CD34 also expressed on embryonic fibroblasts and nervous tissue | 105–120 | − | − | − | − | + | − | − | − | − | + | 1q32 | CD34 | |
| CD35 | CR1, C3b/C4b receptor | Myeloid | C3b, C4b, iC3, iC4 | C3b/C4b receptor; promotes phagocytosis (immune adherence); plays a major role in removal of immune complexes; regulates complement activation | 160–250 | + | + | + | − | + | + | − | + | 1q32 | CD35 | |||
| CD36 | GpIIIb, GPIV | Platelet | Thrombospondin | Recognition and phagocytosis of apoptotic cells; involved in platelet adhesion and aggregation; cytoadherence of plasmodium falciparum-infected erythrocytes | 90 | − | − | + | − | + | + | − | + | + | − | 7q11.2 | CD36 | |
| CD37 | gp52–40 | B | CD53, CD81, CD82, MHC II | Involved in signal transduction | 40–52/40–52 | + | + | − | + | + | − | − | 19p13-q13.4 | CD37 | ||||
| CD38 | ADP-ribosyl cyclase, T10 | B | CD31 | Regulates cell activation and proliferation; involved in lymphocyte and endothelial cell adhesion | 45/45 | + | + | + | + | + | − | 4p15 | CD38 | |||||
| CD39 | None | B | ADP/ATP | May protect cells from lytic effects of extracellular ATP | 80/80 | ⊕ | + | + | + | + | − | + | + | 10q24 | CD39 | |||
| CD40 | Bp50 | B | CD40L | Involved in B cell growth, differentiation and isotype switching; potent rescue signal from apoptosis; promotes cytokine production | 85/48 | − | + | + | − | + | + | − | − | + | + | 20q12-q13.2 | CD40 | |
| CD41 | GPIIb, αIIb integrin | Platelet | Fg, Fn, vWF | CD41/CD61 complex plays a central role in platelet activation and aggregation | 135/120, 23 | − | − | − | − | + | − | − | + | − | − | − | 17q21.32 | CD41 |
| CD42a | GPIX | Platelet | vWF, thrombin | Forms complex with GPIbα GPIbβ, and GPV, which binds to vWF and thrombin | 22/17–22 | − | − | − | − | + | − | − | + | − | − | − | 3q21 | CD42a |
| CD42b | GPIbα | Platelet | vWF, thrombin | Forms complex with GPIX, GPIbβ, and GPV, which binds to vWF and thrombin | 160/145 | − | − | − | − | + | − | − | + | − | − | − | 17pter-p12 | CD42b |
| CD42c | GPIbβ | Platelet | vWF, thrombin | Forms complex with GPIX, GPIbα, and GPV, which binds to vWF and thrombin | 160/24 | − | − | − | − | + | − | − | + | − | − | − | 22q11.21 | CD42c |
| CD42d | GPV | Platelet | vWF, thrombin | Forms complex with GPIX, GPIbα, and GPIbβ, which binds to vWF and thrombin | 82/82 | − | − | − | − | + | − | − | + | − | − | − | 3 | CD42d |
| CD43 | Sialophorin, leukosialin | Non-lineage | Hyaluronan | Anti-adhesion molecules mediates repulsion between leucotyes and other cells; under some circumstances it may act as an adhesion molecule | 95–135/95–135 | + | + | + | + | + | + | − | 16p11.2 | CD43 | ||||
| CD44 | ECMRII, H-CAM, Pgp-1 | Adhesion structure | Hyaluronan | An adhesion molecule in lymphocyte-endothelial cell interaction; a differentiation antigen during lymphopoiesis; a potential marker of malignancy and metastasis | 85/- | + | + | + | + | + | − | + | + | + | 11p13 | CD44 | ||
| CD44R | CD44v, CD44v9 | Adhesion structure | Hyaluronan | Involved in adhesion of leukocytes and endothelial cells; leukocyte homing | 85/200/- | ⊕ | + | 11p13 | CD44R | |||||||||
| CD45 | LCA, T200 | Non-lineage | p56, p59, Src kinases | Critical requirements for TCR- and BCR-mediated activation; possible requirement for receptor-mediated activation in other leukocytes | 180220/- | + | + | + | + | + | + | + | − | − | − | − | 1q31-q32 | CD45 |
| CD45RA | Non-lineage | p56, p59, Src kinases | Critical requirement for TCR- and BCR-mediated activation; expressed on resting/naive T cells; possible requirement for receptor-mediated activation in other leukocytes | 220 | + | + | + | + | + | + | − | − | − | − | − | 1q31-q32 | CD45RA | |
| CD45RB | Non-lineage | p45, p59, Src kinases | Critical requirement for TCR- and BCR-mediated activation; possible requirement for receptor-mediated activation in other leukocytes | 220 | + | + | + | + | + | + | + | − | + | − | − | 1q31-q32 | CD45RB | |
| CD45RC | Non-lineage | p56, p59, Src kinases | Critical requirement for TCR- and BCR-mediated activation; possible requirement for receptor-mediated activation in other leukocytes | 220 | + | + | + | + | + | + | − | − | − | − | − | 1q31-q32 | CD45RC | |
| CD45RO | UCHL-1 | Non-lineage | p56, p59, Src kinases | Critical requirement for TCR- and BCR-mediated activation; expressed on activated/momery T cells; possible requirement for receptor-mediated activation in other leukocytes | 180 | ⊕ | + | + | + | + | + | + | − | − | − | − | 1q31-q32 | CD45RO |
| CD46 | MCP | Non-lineage | SCR | Co-factor for factor I proteolytic cleavage of C3b and C4b | 52–58/64–68 | + | + | + | + | + | + | − | + | + | 1q32 | CD46 | ||
| CD47 | gp42, IAP, OA3 | Adhesion structure | SIRP | Adhesion molecule; thrombospondin receptor | 45–60/50–55 | + | + | + | + | + | + | + | + | + | 3q13.1-q13.2 | CD47 | ||
| CD47R | MEM-133 | Non-lineage | CDw149 mAbs actually recognized with low affinity the CD47 glycoprotein | 120/- | + | + | + | + | + | + | + | + | 3q13.1-q13.2 | CD47R | ||||
| CD48 | Blast-1, Hu lym3 | Non-lineage | CD2, lck, fyn | Adhesion molecule; acts as an accessory molecule for γ/δ T-cell recognition; as predicted for α/β T-cell antigen recognition | 45/45 | + | + | + | + | + | − | − | − | 1q21.3-q22 | CD48 | |||
| CD49a | VLA-1α, α1 integrin | Adhesion structure | Collagen, laminin-1 | Adhesion receptor | 200/200 | ⊕ | − | ⊕ | − | − | − | − | − | 5 | CD49a | |||
| CD49b | VLA-2α, GPIa | Adhesion structure | Collagen, laminin | Adhesion molecule | 150/160 | ⊕ | + | + | + | + | − | + | − | + | + | 5q23–31 | CD49b | |
| CD49c | VLA-3α, α3 integrin | Adhesion structure | laminin-5, Fn, collagen | Component of adhesion receptor; associates with TM4 of protein; may be involved in signal transduction | 145–150/125,30 | − | − | + | + | + | 17q21.31 | CD49c | ||||||
| CD49d | VLA-4α, α4 integrin | Adhesion structure | CD106, MAdCAM | Cell adhesion; lymphocyte migration; tethering or rolling and homing of T cells | 145/150 | + | + | + | + | + | ⊕ | − | − | − | + | 2q31-q32 | CD49d | |
| CD49e | VLA-5α, α5 integrin | Adhesion structure | Fibronectin, invasin | Adhesion molecule | 160/135, 25 | + | + | + | + | + | − | + | + | 12q11-q13 | CD49e | |||
| CD49f | VLA-6α, α6 integrin, gplc | Adhesion structure | Laminins, invasin | Component of adhesion receptor; CD49f/CD29-mediated T cell binding to laminin receptor provides a co-stimulatory signal to T cells for activation and proliferation | 150/125 | + | + | + | + | + | + | 2p14-q14.3 | CD49f | |||||
| CD50 | ICAM-3 | Adhesion structure | LFA-1, integrin ad/b2 | Co-stimulatory molecule; regulates LFA-1/ICAM-1 and integrin-β1-dependent pathways adhesion; soluble form can be detected in the blood | 110/140/- | + | + | + | + | + | + | − | − | + | − | 19p13.3-p13.2 | CD50 | |
| CD51 | Integrin αv, VNR-α | Platelet | Arg-Gly-Asp | Involved in cell adhesion and signal transduction; role in bone metabolism and apoptosis; possible role in infection | 150/124, 24 | + | − | + | + | 2q31-q32 | CD51 | |||||||
| CD52 | CAMPATH-1, HE5 | Non-lineage | CD52 antibodies are remarkably lytic for target cells, both with human complement and by antibody-dependent cellular cytotoxicity | 25–29/25–29 | + | + | + | + | − | − | + | 1p36 | CD52 | |||||
| CD53 | Non-lineage | VLA-4, HLA-DR | Signal transduction; CD53 cross-linking promotes activation of B cells | 32–42/ | + | + | − | + | + | + | + | − | − | + | − | 1p31-p12 | CD53 | |
| CD54 | ICAM-1 | Adhesion structure | LFA-1, Mac-1, rhinovirus | Involved in immune reaction and/or inflammation; receptor for Rhinovirus or RBCs infected with malarial parasite; soluble form can be detected in the blood | 90/95 | + | + | + | + | 19p13.3-p13.2 | CD54 | |||||||
| CD55 | DAF | Non-lineage | SCR, CD97 | Complement regulation by decay acceleration; ligand or protective molecule in fertilization; involved in signal transduction; soluble form can be detected in plasma and body fluid | 5570/80 | + | + | + | + | + | + | + | + | + | + | 1q32 | CD55 | |
| CD56 | Leu-19, NKH-1, NCAM | NK | NCAM, Heparin sulfate | Homophilic and heterophilic adhesion | 140 | + | + | 11q23-q24 | CD56 | |||||||||
| CD57 | HNK1, Leu-7 | NK | L-selectin, P-selectin Laminin | Cell-cell adhesion | 110–115 | + | CD57 | |||||||||||
| CD58 | LFA-3 | Adhesion structure | CD2 | Mediates adhesion between killer and target cells, antigen-presenting cells and T cells; activation of killer cells; co-stimulatory molecule | 55–70 | + | + | + | + | + | + | + | + | + | 1p13 | CD58 | ||
| CD59 | IF5Ag, H19 | Non-lineage | C8-α, C9, lck, fyn | Associates with C9, inhibiting incorporation into C5b-8 preventing the completion of MAC formation | 18–25 | + | + | + | + | + | 11p13 | CD59 | ||||||
| CD60a | GD3 | Carbohydrate and lectin | Induces mitochondrial permeability transition during apoptosis; marker for malignant melanomas | + | + | + | + | + | − | CD60a | ||||||||
| CD60b | 9–0-acetyl CD3 | Carbohydrate and lectin | 9–0-acetyl-CD3 | mAbs immunoreactive to CD60b have co-mitogenic activity of synovial T cells; also observed on some breast carcinomas and melanomas | 90–94/120 | + | + | + | + | + | CD60b | |||||||
| CD60c | 7-0-acetyl CD3 | Carbohydrate and lectin | T cell activation receptor; T cell activation by CD60c does not require co-stimulatory signals | + | + | + | CD60c | |||||||||||
| CD61 | GP IIIa, β3 integrin | Platelet | Fibrinogen | CD41/61 mediates attachment of cells to diverse matrix proteins | 90110 | + | + | + | 17q21.32 | CD61 | ||||||||
| CD62E | E-selectin | Adhesion structure | (CD15s) | Mediates leukocyte rolling on activated endothelium at inflammatory sites; may support cell adhesion during hematogenous metastasis and play a role in angiogenesis | 115 | + | 1q22-q25 | CD62E | ||||||||||
| CD62L | L-selectin | Adhesion structure | CD34, GlyCAM-1, M | Mediates lymphocyte homing to high endothelial venules or peripheral lymphoid tissue and leukocyte rolling on activated endothelium at inflammatory sites | 74 | + | + | + | − | + | + | 1q23-q25 | CD62L | |||||
| CD62P | P-selectin, GMP-140 | Platelet | CD162, CD24 | Interaction of CD62P and CD162 mediates tethering and rolling of leukocytes on the surface of activated endothelial cells; mediates rolling of platelets on endothelial cells | 120 | + | + | 1q22-q25 | CD62P | |||||||||
| CD63 | LIMP, MLA1, gp55 | Platelet | VLA-3, VLA-6, CD81 | CD63 gene may play a role in tumor suppression; expression of CD63 in melanoma cells reduces metastasis | 40–60 | + | + | + | + | + | 12-q12-q13 | CD63 | ||||||
| CD64 | FCRI | Myeloid | IgG | Receptor-mediated endocytosis of IgG-antigen complexes; antigen capture for presentation to T cells. ADCC | 72 | − | − | + | − | + | + | − | − | − | − | 1q21.2-q21.3 | CD64 | |
| CD65 | Ceramide, VIM-2 | Myeloid | E-selectin | Function unknown | + | + | CD65 | |||||||||||
| CD65s | Sialylated-CD65, VIM2 | Myeloid | Possibly E- or P-selectin | VIM2 antibody has been described to inhibit phagocytosis and to induce phagocyte calcium flux and oxidative burst | − | − | − | + | + | − | − | − | CD65s | |||||
| CD66a | NCA-160, BGP | Myeloid | Homophilic and heterophilic adhesion; E-selectin binding; capable of activating granulocytes; functions as a receptor for Neisseria gonorrhea | 140–180 | − | − | − | + | − | − | − | + | CD66a | |||||
| CD66b | CD67, CGM6, NCA-95 | Myeloid | Capable of heterophilic adhesion and transmembrane signaling; capable of activating neutrophils | 95100 | − | − | − | + | − | − | − | 19q13.2 | CD66b | |||||
| CD66c | NCA, NCA-50/90 | Myeloid | Homophilic and heterophilic adhesion, E-selectin binding; capable of activating granulocytes; functions as a receptor for Neisseria gonorrhea | 90 | − | − | − | + | − | − | − | + | 19q13.2 | CD66c | ||||
| CD66d | CGM1 | Myeloid | Capable of activating granulocytes. Functions as a receptor for Neisseria gonorrhea | 35 | − | − | − | + | − | − | − | 19q13.2 | CD66d | |||||
| CD66e | CEA | Myeloid | Homphilic and heterophilic adhesion | 180200 | − | − | − | − | − | − | + | 19q13.2-q13.2 | CD66e | |||||
| CD66f | SP-1, PSG | Myeloid | Unclear, may be involved in immune regulation and regulation and protection of fetus from maternal immune system; necessary for successful pregnancy | 54–72 | − | + | 19q13.2 | CD66f | ||||||||||
| CD68 | gp110, macrosialin | Myeloid | LDL | Lysosomal membrane glycoprotein (LAMP 1 group); possible receptor | 110 | +c | +c | +c | +c | +c | +c | − | − | 17p13 | CD68 | |||
| CD69 | AIM, EA 1, MLR3, gp34/28 | NK | Involved in lymphocyte, monocyte, and platelet activation | 60 | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ | + | 12p13-p12 | CD69 | ||||||
| CD70 | Ki-24 | Non-lineage | CD27 | Co-stimulation of T and/or B cells; enhances the proliferation of cytotoxic T cells and cytokine production. Co-stimulates B cell proliferation and Ig production | 55–170 | ⊕ | ⊕ | − | − | − | − | − | − | − | − | − | 19p13 | CD70 |
| CD71 | T9, Transferrin receptor | Non-lineage | Transferrin | Controls the supply of iron uptake during proliferation | 190 | − | − | − | − | + | − | + | 3q26.2-qter | CD71 | ||||
| CD72 | Ly-19.2, Ly-32.2, Lyb-2 | B | CDS | Plays a role in downregulation of signaling through the BCR on B cells as a regulator of signaling thresholds | 43/39 | − | + | + | − | + | − | − | − | 9p | CD72 | |||
| CD73 | Ecto-5-nuclotidase | B | AMP | Hydrolyzes adenosine monophosphate into adenosine; can mediate co-stimulatory signals in T cell activation | 69–72 | + | + | + | − | + | − | − | − | − | + | + | 6q14-q21 | CD73 |
| CD74 | invariant chain | B | HLA-DR, CD44 | Intracellular sorting of MHC class II molecules; also known as Class II specific chaperone li | 41 | + | + | + | + | + | 5q32 | CD74 | ||||||
| CD75 | Sialo-masked lactosamine | Carbohydrate and lectin | CD75 is newly clustered including CDw75 and CDw76, CDw76 has been deleted | − | + | − | − | + | − | − | + | − | − | CD75 | ||||
| CD75s | a2, 6 sialylated lactosamine | Carbohydrate and lectin | CD22 (proposed) | May be involved in regulation of CD95-mediated apoptosis and may be important for infection by a lymphotropic virus | + | + | − | − | + | + | − | + | + | + | CD75s | |||
| CD77 | Pk antigen/BLA/CTH/Gb3 | B | Receptor for Shiga toxin | Cross-linking of CD77 induces apoptosis in Burkitt's lymphoma cells | 1 | − | + | − | − | − | − | − | − | + | + | CD77 | ||
| CD79a | Ig α/MB1 | B | Ig/CD5/CD19/CD22/CD79b | Transmits signals into cytoplasm upon antigen-binding to surface lgs | 40–45 | + | 19q13.2 | CD79a | ||||||||||
| CD79b | Ig β/B29, BCR | B | Ig/CD5/CD19/CD22/CD79a | B cell antigen receptor (BCR) mediates the response of B cells to foreign antigens and determines the fate of B cells during development and differentiation | -/37 | − | + | − | − | − | − | − | − | − | + | 17q23 | CD79b | |
| CD80 | B7-1/BB1 | B | CD28/CD152 (CTLA-4) | Co-regulation of T-cell activation with CD86 | 60/- | ⊕ | ⊕ | + | − | − | + | − | − | − | − | − | 3q13.3-q21 | CD80 |
| CD81 | TAPA-1 | B | Leu-13/CD19/CD21 | Member of CD19/CD21/Leu-13 signal transduction complex. #Or ly on eosinophils, not neutrophils | 26/- | + | + | + | + | + | + | +# | + | + | 11p15 | CD81 | ||
| CD82 | 4F9/C33/IA4/KAI1/R2 | B | Signal transduction. #Also associates with MHC class I and II, β1 integrins, CD4 and CD8 | 45–90/- | + | + | + | + | + | + | + | − | + | + | 11p11.2 | CD82 | ||
| CD83 | HB15 | B | Unknown | Function unknown | -/43 | − | + | + | − | − | − | − | − | − | − | 6p23 | CD83 | |
| CD84 | None | B | Unknown | Function unkown, some indication that it may be a signaling molecule | 68–80 | + | + | − | + | − | − | − | − | 1q24 | CD84 | |||
| CD85a* | ILT5/LIR3/HL9 | Dendritic cell | HLA class I | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | + | − | + | − | + | + | + | − | − | − | − | 19q13.4 | CD85a* | |
| CD85b* | ILT8 | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity | 19ql3.4 | CD85b* | ||||||||||||
| CD85c* | LIR8 | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity | 19ql3.4 | CD85c* | ||||||||||||
| CD85d* | ILT4/LIR2/MIR 10 | Dendritic cell | HLA class I | Contains I TIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 110 | − | − | + | − | − | + | + | − | − | − | − | 19ql3.4 | CD85d* |
| CD85e* | ILT6/LIR4 | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity | 19ql3.4 | CD85e* | ||||||||||||
| CD85f* | ILT11 | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity. Mainly expressed on PBL | 19ql3.4 | CD85f* | ||||||||||||
| CD85g* | ILT7 | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity | 19ql3.4 | CD85g* | ||||||||||||
| CD85h* | ILT1/LIR7 | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity. Expressed on myeloid cells and some NK cells | 19ql3.4 | CD85h* | ||||||||||||
| CD85i* | LIR6a | NK | FcRγ | Involved with activation of NK-mediated cytotoxicity | 19ql3.4 | CD85i* | ||||||||||||
| CD85j* | ILT2/LIR1/MIR7 | Dendritic cell | HLA class I | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 110 | + | + | + | + | − | + | + | − | − | − | − | 19ql3.4 | CD85J* |
| CD85k* | ILT3/LIR5/HM18 | Dendritic cell | HLA class I | Ligation of CD85K induces an inhibitory signal via recruitment of SHP-1 phosphatase | 60 | − | − | + | − | + | + | + | − | − | − | − | 19ql3.4 | CD85k* |
| CD85i* | ILT9 | NK | FcRγ | Binds FcRγ | 19ql3.4 | CD85L* | ||||||||||||
| CD85m* | ILT10 | NK | FcRγ | Binds FcRγ | 19ql3.4 | CD85m* | ||||||||||||
| CD86 | B7-2/B70 | B | CD8S/CD152 (CTLA-4) | Co-regulator of T cell activation with CD80 | -/80 | ⊕ | ⊕ | + | − | − | + | − | − | − | + | − | 3q21 | CD86 |
| CD87 | uPAR | Myeloid | uPA/Pro-UPA/vitronectin | CD87 serves as the cellular receptor for pro-uPA and uPA | 35–68/32–66 | + | − | + | + | − | + | + | − | − | + | − | 19ql3 | CD87 |
| CD88 | C5aR | Myeloid | C5a/C5a(desArg) | C5a-mediated inflammation; activation of granulocytes | 43/- | − | − | + | − | − | + | + | − | − | + | + | 19ql3.3-ql 3.4 | CD88 |
| CD89 | IgA FC receptor | Myeloid | IgAl/IgA2 | Induces phagocytosis, degranulation, respiratory burst, and the killing of microorganisms | 45–100/45–100 | − | − | − | − | + | + | − | − | − | − | 19ql3.2-ql 3.4 | CD89 | |
| CD90 | Thy-1 | Endothelial cell | CD45/lck/fyn/P100 | May contribute to lymphocyte co-stimulation, inhibition of stem cell proliferation/differentiation and neuron memory formation | 25–35/25–35 | − | − | − | + | − | − | − | − | + | − | 11q22.3-q23 | CD90 | |
| CD91 | ALPHA2M-R/LRP | Myeloid | ALPHA2M/LDLs | Endocytosis-mediating receptor expressed in coated pits. #Expressed on erythroblast/reticulocytes | 600/- | − | − | − | +# | + | − | − | − | − | + | 12q13-q14 | CD91 | |
| CD92 | None | Myeloid | Unknown | Function unkown | 70/70 | + | + | + | + | − | − | + | + | CD92 | ||||
| CDw93 | None | Myeloid | Unknown | Function unknown | 110/120 | − | − | − | − | − | + | + | − | − | + | − | CDw93 | |
| CD94 | Kp43 | NK | HLA class I | Assembled with other C-type lectins (NKG2) forms inhibitory or activating receptors for HLA class I | 70, 30 | + | − | + | − | − | − | − | − | − | 12q13 | CD94 | ||
| CD95 | APO-1, FAS, TNFRF6 | Cytokine receptor | Fas ligand | Receptor molecule for Fas ligand, which mediates apoptosis-inducing signals | 45, 90, 200/45 | + | + | + | + | + | − | − | 10q24.1 | CD95 | ||||
| CD96 | TACTILE | NK | Adhesion of activated T and NK cells during the late phase of immune response; weakly expressed by peripheral resting NK or T cells, upregulated after activation | 160/- | ⊕ | − | ⊕ | − | − | − | − | CD96 | ||||||
| CD97 | Non-lineage | CD55 | Member of the EGF-TM7 family; weakly expressed on resting lymphocytes, upregulated by activation | /28, 75–85 | ⊕ | ⊕ | + | ⊕ | + | + | − | − | 19p13.2-p13.12 | CD97 | ||||
| CD98 | 4F2, FRP-1, RL-388 | Non-lineage | actin | Possible amino acid transporter; broad reactivity on activated and transformed cells, not hematopoietic specific, and found at lower levels on quiescent cells | 125/80, 45 | + | + | + | + | + | + | − | + | + | 11q13 | CD98 | ||
| CD99 | MIC2, E2 | T | Modulates T-cell adhesion; induces apoptosis of double-positive thymocytes; expressed on all hemological cells and present on many other cell types | 32/32 | + | + | + | + | − | + | + | + | + | Xp22.32, Yp11.3 | CD99 | |||
| CD99R | CD99 Mab restricted | T | Modulates T-cell adhesion; induces apoptosis of double-positive thymocytes | 32/32 | + | − | + | − | + | − | − | 9q22-q31 | CD99R | |||||
| CD100 | SEMA4D | Non-lineage | CD45, serine kinase | Co-stimulatory molecule for T-cells; increases PMA, CD3, and CD2 induced T cell proliferation; Soluble form is 120 kD | 300/150 | + | + | − | + | − | + | + | − | − | − | 9q22-q31 | CD100 | |
| CD101 | IGSF2, P126, V7 | Myeloid | Co-stimulatory molecule; antibodies against CD101 inhibit allogenic T cell responses and co-stimulate T cell proliferation with suboptimal anti-CD3 activation | 240/120 | ⊕ | − | + | − | + | + | − | − | 1p13 | CD101 | ||||
| CD102 | ICAM-2 | Adhesion structure | LFA-1, CD11b/CD18 | Provides co-stimulatory signal in immune response; lymphocyte recirculation; expressed on some resting lymphocytes | 55–65/ | + | + | + | + | − | + | − | + | 17q23-q25 | CD102 | |||
| CD103 | HML-1, integrin αE | Adhesion structure | E-cadherin; integrin β7 | Expressed on intestinal intraepithelial lymphocytes, lamina propria T cells in intestine; stimulation of PBL with PHA induce CD103 expression | 175/150,25 | ⊕ | − | − | − | − | − | − | − | 17p13 | CD103 | |||
| CD104 | β4 integrin chain, TSP-180 | Adhesion structure | Laminins (I, II, IV, V), CD49F | Hemidesmosomal CD49f/CD104 (α6β4 integrin) plays an important role in the adhesion of epithelia to basement membranes. #CD4-CD8-pre-T cells | 205/220 | − | − | − | +# | + | − | − | − | + | + | 17q11-qter | CD104 | |
| CD105 | Endoglin | Endothelial cell | TGF-β 1, TGF-β 3 | Regulatory component of the TGF β receptor complex; modulator of cellular responses to TGF-1 β | 180/90 | − | − | − | + | + | − | − | − | + | 9q33-q34.1 | CD105 | ||
| CD106 | VCAM-1, INCAM-110 | Endothelial cell | Integrin α4β 1 | Leukocyte adhesion, transmigration and co-stimulation of T cell proliferation; expressed on activated endothelial cells, follicular dendritic cells, and certain tissue macrophages# | 110/110 | − | − | +# | − | +# | − | − | − | ⊕ | 1p32-p31 | CD106 | ||
| CD107a | LAMP-1 | Platelet | Possible role in cell adhesion; highly metastatic tumor cells express more LAMP molecules on the cell surface than poorly metastatic cells; expressed on lysosomal membrane | 100–120/ | ⊕ | − | − | + | ⊕ | ⊕ | − | ⊕ | + | 13q34 | CD107a | |||
| CD107b | LAMP-2 | Platelet | Possible role in cell adhesion; highly metastatic tumor cells express more LAMP molecules on the cell surface than poorly metastatic cells; expressed on lysosomal membrane | 100–120/ | − | − | − | − | ⊕ | ⊕ | − | ⊕ | Xq24 | CD107b | ||||
| CD108 | SEMA7A, JMH | Non-lineage | CD232 | Function unknown; carries JMH blood group antigen; expressed at low levels on circulating lymphocytes, at moderately high levels by cells and lymphoblastic cell lines | 76/80 | + | + | − | − | + | 15q22.3-q23 | CD108 | ||||||
| CD109 | 8A3, 7D1, E123 | Endothelial cell | Function unknown | 170/170 | ⊕ | − | − | + | − | − | ⊕ | − | + | + | CD109 | |||
| CD110 | TPO-R, MPL, C-MPL | Platelet | TPO | Receptor for TPO. Receptor binding results in the prevention of apoptosis, stimulation of cell growth and differentiation of megakaryocyte and platelet formation | 82–92/ | − | − | − | − | + | − | − | + | − | 1p34 | CD110 | ||
| CD111 | HveC, PRR1, PVRL1, nectin1 | Myeloid | gD, nectin3, afadin | Intercellular adhesion molecule; involved in epithelial cell physiology; pan-alphaherpes virus entry receptor | -/75 | − | − | + | + | + | − | + | + | + | 11q23-q24 | CD111 | ||
| CD112 | HveB, PRR2, PVRL2, nectin2 | Myeloid | PRR3, afadin | Homophilic adhesion receptor that could play a role in the regulation of hematopoietic/endothelial cell functions; involved in cell to cell spreading of viruses | 72, 64/72, 64 | − | + | + | + | + | + | − | + | + | 19q13.2–13.4 | CD112 | ||
| CD114 | CSF3R, G-CSFR, HG-CSFR | Myeloid | G-CSF, Jak1, Jak2 | Regulates myeloid proliferation and differentiation | 130 | − | − | − | + | + | + | − | + | 1p35-p34.3 | CD114 | |||
| CD115 | c-fms, CSF-1R, M-CSFR | Myeloid | CSF-1 | Receptor for CSF-1 (macrophage colony stimulating factor); mediates all of the biological effects of this cytokine | 150 | − | − | − | + | + | − | − | − | 5q33.2–33.3 | CD115 | |||
| CD116 | GM-CSFRα | CD/CKR | GM-CSF | Primary binding subunit of GM-CSF with low affinity and binds it with high affinity when it is coexpressed with the common beta subunit CDw131 | 80 | − | − | + | − | + | + | + | − | − | − | Xp22.32 or Yp11.3 | CD116 | |
| CD117 | c-KIT SCRF | CK/CKR | SCF, MGF, KL | Growth factor receptor, tyrosine kinase | 145 | − | − | − | − | + | − | − | − | − | − | 4q11-q12 | CD117 | |
| CDw119 | iFN-γR, IFNγRa | CK/CKR | IFNγ | Interferon γ binding | 80–95 | + | + | + | + | + | + | + | − | + | + | 6q23-q24 | CDw119 | |
| CD120a | TNFRI, p55 | CK/CKR | TNF, TRADD, TRAF, RiP, LTa | Programmed cell death anti-viral activity; receptor for TNF | 55 | + | + | + | + | + | + | + | − | + | + | 12p13.2 | CD120a | |
| CD120b | TNFRII, p75, TNFR p80 | CK/CKR | TNF, TRADD, TRAF, RiP, LTa | Programmed cell death anti-viral activity; receptor for TNF | 75 | + | + | + | + | + | + | − | + | + | 1p36.3-p36.2 | CD120b | ||
| CD121a | IL-1R type 1 | CK/CKR | II-1α and II-1β | IL-1 signaling | 75–85/75–85 | + | + | − | − | − | − | − | − | − | + | 2q12 | CD121a | |
| CD121b | IL-1R type 2 | CK/CKR | IL-1β, IL-1Rα, IL-1α | Negative regulator of IL-1 | 60–68/60–68 | + | + | + | + | − | − | − | + | 2q12-q22 | CD121b | |||
| CD122 | IL2Rβ | CK/CKR | IL-2, IL-15, CD25, CD132 | Critical component of IL-2 and IL-15-mediated signaling | 70–75/- | + | + | + | + | − | − | − | − | 22g13.1 | CD122 | |||
| CD123 | IL-3Rα subunit | CK/CKR | IL-3 | Primary low affinity binding subunit of IL-3 receptor | 70 | − | − | + | + | + | + | + | Xp22.3 or Yp11.3 | CD123 | ||||
| CD124 | IL-4R | CK/CKR | IL-4, IL-13 | Receptor subunit for IL-4 and IL-13; #expression on B cells is upregulated by LPs, anti-IgM or IL-4; #on T cells is increased by stimulation with ConA or IL-4 | 140/- | ⊕# | ⊕# | − | + | + | − | − | − | 16p11.2–12.1 | CD124 | |||
| CD125 | IL-5Rα | CK/CKR | IL-5 | Low affinity receptor for IL-5; alpha chain of IL-5 receptor; expressed on eosinophils and basophils | 60/- | − | ⊕ | − | − | + | − | − | − | 3p26-p24 | CD125 | |||
| CD126 | IL-6R | CK/CKR | IL-6 | Required, in association with gp130(CD130), for mediating biological activities of interleukin-6; expressed on hepatocytes and some non-hematopoietic cells | 80/80 | + | ⊕ | − | + | − | − | − | − | 1q21 | CD126 | |||
| CD127 | IL-7Rα | CK/CKR | IL-7, CD132, fyn, yn, Jak1 | Specific receptor for IL-7; expression downregulated following T cell activation | 65 90/- | + | + | + | − | − | − | − | 5p13 | CD127 | ||||
| CD128a | II-8RA, CXCR1 | CK/CKR | IL-8 | Critical regulation of IL-8 mediated neutrophil chemotaxis and activation; potential role in angiogenesis | 44–59/67–70 | + | − | + | − | + | + | + | + | 2q35 | CD128a | |||
| CD128b | IL-8RB, CXCR2 | CK/CKR | IL-8 | Critical regulators of IL-8 mediated neutrophil chemotaxis and activation; potential role in angiogenesis | 44–59/67–70 | + | − | + | − | + | + | + | + | 2q35 | CD128b | |||
| CD130 | gp130 | CK/CKR | Oncostatin M | Required for transducing biological activities of IL-6, IL-11, LIP, ciliary neutropholic factor, oncostatin M, and cardiotrophin-1 | 130–140/130–140 | + | + | + | + | + | + | + | 5q11 | CD130 | ||||
| CD131 | Common beta subunit | CK/CKR | CD123, CD125, CD116 | Key signal transducing molecule of the IL-3, GM-CSF, and IL-5 receptors; expressed on early B cells and early progenitors | 120–140/- | − | − | − | + | + | + | 22q13.1 | CD131 | |||||
| CD132 | IL-2Rγ | CK/CKR | IL-12 | Common subunit of IL-2, IL-4, IL-7, IL-9, IL-15 receptors; mutation causes X-linked severe combined immunodeficiency (XSCID) | 65 70/- | + | + | + | + | + | + | Xq13.1 | CD132 | |||||
| CD133 | AC133 | Stem Cell | N/A | Used for positive selection of hematopoietic stem and progenitor cells for transplantation studies | 120 | − | − | − | − | + | − | − | − | − | + | + | 4p16.2 | CD133 |
| CD134 | OX40 | CK/CKR | 0X40 ligand | Receptor for 0X40 ligand; co-stimulatory signal transducer of T cell receptor-mediated activation, cell adhesion | 48–50/- | ⊕ | − | − | 1p36 | CD134 | ||||||||
| CD135 | Flt3, FLK2, STK1 | CK/CKR | FL | Receptor tyrosine kinase; co-stimulatory molecule; survival receptor; growth factor receptor for early hematopoietic progenitors | 130/155–160 | − | − | − | − | + | + | − | − | − | 13q12 | CD135 | ||
| CDw136 | MSP-R, RON | CK/CKR | MSP, HGFI | Chemotactic migration, morphological change, cell growth, cytokine induction, phagocytosis, and cell differentiation | 180/150, 40 | + | + | 13p21.3 | CDw136 | |||||||||
| CDw137 | 4-1BB, ILA | CK/CKR | 4-1BB ligand | Receptor for 4-1BB ligand; co-stimulatory molecule | 85/39 | ⊕ | + | − | + | − | + | 1p36 | CDw137 | |||||
| CD138 | Syndecan1 | B | Extracellular matrix receptor; co-receptor for fibroblast growth factor signaling receptors; #expressed on plasma cells | -/165150 | − | +# | − | − | − | − | − | + | 2p24.1 | CD138 | ||||
| CD139 | None | B | Function unknown | 209/228 | − | + | + | − | + | + | + | + | CD139 | |||||
| CD140a | PDGF a receptor | Endothelial cell | PDGF | Involved in signal transduction associated with PDGF receptors; expressed on mesenchymal cells | 160, 180/- | − | − | − | − | − | + | − | 4q11-q13 | CD140a | ||||
| CD140b | PDGF B receptor | Endothelial cell | PDGF | Involved in signal transduction associated with PDGF receptors; expressed on mesenchymal cells | 160, 180/- | − | − | − | + | + | − | − | + | 5q31-q32 | CD140b | |||
| D141 | Thrombomodulin | Endothelial cell | Thrombin, protein C | Critical for activation of protein C and initiation of the protein C anticoagulant pathway; co-factor in the thrombin-mediated activation of protein C | 75/105 | − | − | − | + | + | + | + | + | 20p12-cen | CD141 | |||
| CD142 | Tissue factor | Endothelial cell | Factor VIlla, factor Xa/TFPI | Initiator of the blood clotting cascade; cell surface receptor/cofactor for factor VII; can be induced by inflammatory mediators | 45–47/45–47 | − | − | − | − | − | − | + | + | 1p22-p21 | CD142 | |||
| CD143 | ACE | Endothelial cell | ANG-1, bradykinin | Angiotensin-converting enzyme, peptidyl dipeptidase, is necessary for spermatozoa to bind to eggs | 90, 170/90, 170 | + | − | − | − | − | − | − | + | + | 17q2 | CD143 | ||
| CD144 | VE-cadherin, cadherin-5 | Endothelial cell | β-catenin, pl20 CAS | Controls endothelial permeability, growth, migration, and contact inhibition of cell growth; expressed only on endothelial cells | 135/130 | − | − | − | − | − | + | − | CD 144 | |||||
| CDwl45 | None | Endothelial cell | Highly expressed on endothelial cells; antibodies were originally raised against human urinary bladder carcinoma cells | 25, 90, 110 | − | − | − | − | − | + | CDwl45 | |||||||
| CD146 | Muc 18 S-endo | Endothelial cell | Potential adhesion molecule; expressed by melanoma, smooth muscle, and intermeciate trophoblasts | 118/130 | ⊕ | − | − | − | − | − | + | llq23.3 | CD146 | |||||
| CD147 | Neurothelin, OX-47 | Endothelial cell | Potential adhesion molecule; involved in regulation of T cell function | 50–60/55–95 | | | | | + | + | + | + | + | + | 10pl3.3 | CD147 | ||||
| CD148 | HPTPn, p260 DEP-1 | Non-lineage | HPTP-etc/Dep-1 involved in contact inhibition of cell growth; chromosomal location region frequently detailed in carcinoma | 200–260/200–260 | + | + | + | + | + | + | llpll.2 | CD148 | ||||||
| CD150 | SLAM-1, IPO-3 | Non-lineage | Tyrosine phosphatase CD45 | An important molecule associated with intracellular adaptor protein SAP. Absence of SAP causes X-linked lymphoproliferative disease | 65–85/75–95 | + | + | + | − | − | − | − | − | + | lq22-q23 | CD150 | ||
| CD151 | PET A-3 | Platelet | β1 integrins | Integrin-associated protein; transmembrane signaling | 32/- | − | − | − | + | − | − | + | + | + | llpl5.5 | CD151 | ||
| CD152 | CTLA-4 | T | Receptor for CD80/CD86; negative regulator of T cell activation | 50/33 | ⊕ | ⊕ | − | − | − | − | − | 2q33 | CD152 | |||||
| CD153 | CD30L | T | CD30 | Co-stimulatory signal for peripheral blood T cells | 40 | + | − | ⊕ | + | 9q33 | CD153 | |||||||
| CD154 | CD40L, gp39, TRAP-1, T-BAH | T | Ligand for CD40 | Essential for germinal center formation and antibody class switching; co-stimulatory molecule; regulator of THl generation and function | 33 | ⊕ | − | − | − | − | − | − | Xq26 | CD 154 | ||||
| CD155 | PVR | Myeloid | Polio virus receptor | Possible interaction with CD44 | 60–90 | − | + | − | 19ql3.2 | CD155 | ||||||||
| CD156a | CD156, ADAM8, MS2 | Myeloid | Myeloid | Possible involvement in extravasation of leukocytes | -/69 | + | + | 10q26.3 | CD156a | |||||||||
| CD156b | TACE, AD AM 17 | Adhesion structure | Pro-INFl pro-TGFα, MAD2 | Cleavers the transmembrane form of TNF-α to yield the soluble active form | 100120 | + | − | + | + | + | − | − | + | 2p25 | CD156b | |||
| CD157 | Mo5, BST-1 | Myeloid | A sister molecule of CD3S, a type II membrane protein with identical ectoenzyme activity; a distribution complementary to that of CD3S | 42–15 | + | + | + | + | + | CD157 | ||||||||
| CD158a† | KIR2DL1, p58.1 | NK | HLA-Cw4, 2,5,6 | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 58/58 | + | − | 19ql3.4 | CD158a† | |||||||||
| CD158bl† | KIR2DL2, p58.2 | NK | HLA-3.1, 7, 8 | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 58/58 | + | + | 19ql3.4 | CD158bl† | |||||||||
| CD158b2† | KIR2DL3, p58.3 | NK | HLA-Cw3, 1, 7, 8 | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 58/58 | + | + | 19ql3.4 | CD158b2† | |||||||||
| CD158cl† | KIR2DS6, KIRX | NK | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | + | + | 19ql3.4 | CD158cl† | |||||||||||
| CD158d† | KIR2DL4 | NK | Function unknown | + | 19ql3.4 | CD158d† | ||||||||||||
| CD158 e1/e2† | KIR3DLI/S1, p70 | NK | HLA-Bw4 | Involved in the suppression of NK-mediated cytotoxicity (KIR3DL1); expressed on subsets of NK and cytotoxic cells | 70/70 | + | + | 10ql3.4 | CD158e1/e2† | |||||||||
| CD158f† | KIR2DL5 | NK | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | + | + | 10ql3.4 | CD158f† | |||||||||||
| CDl58g† | KIR2DS5 | NK | Associated with KARAP/DAP12; involved in the activation of NK-mediated cytotoxicity | + | + | 10ql3.4 | CDl58g† | |||||||||||
| CD158h† | KIR2DS1, p50.1 | NK | HLA-C | Associated with KARAP/DAP12; involved in the activation of NK-mediated cytotoxicity | + | + | 10ql3.4 | CD158h† | ||||||||||
| CD158i† | KIR2DS4, p50.3 | NK | HLA-C | Associated with KARAP/DAP12; involved in the activation of NK-mediated cytotoxicity | 50/50 | + | + | 19ql3.4 | CD158i† | |||||||||
| CD158j† | KIR2DS2, p50.2 | NK | HLA-C | Associated with KARAP/DAP12; involved in the activation of NK-mediated cytotoxicity | + | + | 10ql3.4 | CD158j† | ||||||||||
| CD158k† | KIR3DL2, pl40 | NK | HLA-A | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 140/70 | + | + | 10ql3.4 | CD158k† | |||||||||
| CDl58z† | KIR3DL7, KIRCl | NK | Contains ITIM sequences in cytoplasmic tail; involved in the suppression of NK-mediated cytotoxicity | 19ql3.4 | CD158z† | |||||||||||||
| CD159a | NKG2A | NK | HLA-E | CD94/CD159a heterodimer constitutes a potent negative regulator of NK-T and cell activation programs; expressed on subsets of NK and CD8+ (γδ) cells | 70/43 | + | + | 12pl2.3-pl3.1 | CD159a | |||||||||
| CD160 | BY55, NK1, NK28 | T | MHC class I | Cross-linking CD160 with certain mAbs triggers co-stimulatory signals in CDS T cells. CD160 is also expressed on all intestinal intraepithelial lymphocytes | 80/27 | + | – | + | lq42.3 | CD 160 | ||||||||
| CD161 | NKR-P1A | NK | NK cell cytolytic activity; regulation of thymocyte precursor proliferation | 80/40 | + | − | − | + | − | − | − | − | − | CD161 | ||||
| CD162 | PSGL-1 | Adhesion structure | P-selectin | Binds P- and L-selectins; can mediate leukocyte rolling | 160–250/110–120 | + | + | + | + | + | − | − | − | CD 162 | ||||
| CD162R | PENS | NK | L-selectin | Post-translational modification of the P-selectin glycoprotein ligand-1 (CD162); developmentally regulated marker of both immune and neural cells | 240/140 | + | CD162R | |||||||||||
| CD163 | Ml 30, GHI/61, RM3/1 | Myeloid | Expressed on tissue macrophages and LPS activated monocytes | 110 | − | − | − | ⊕ | − | − | − | − | − | CD 163 | ||||
| CD164 | MGC-24, MUC-24 | Adhesion structure | Facilitating the adhesion of human CD34+ cells to stroma and by negatively regulating CD34+CD38−progenitor cell proliferation | 160/80 | + | + | + | + | − | − | + | CD 164 | ||||||
| CD165 | Ad2, gp37 | Adhesion structure | Adhesion of thymocytes to thymic epithelial cells; expressed on many T cell acute lymphoblastic leukemia (ALL) | 37/42 | − | + | − | + | − | + | CD 165 | |||||||
| CD166 | ALCAM, KG-CAM | Adhesion structure | Binds CD6 | Adhesion receptor | 100–105/100–105 | ⊕ | + | ⊕ | − | + | + | CD 166 | ||||||
| CD167a | DDR1 | Adhesion structure | Collagen | Adhesion molecule, DDR1 overexpression in several human cancers suggests a function in tumor progression | 52–62 | + | + | + | 6p21.3 | CD167a | ||||||||
| CD168 | RHAMM | Adhesion structure | CD44 | Involved in adhesion of early thymocyte progenitors to matrix and its interaction with HA can mediate signals to other cell adhesion molecules | 52–125 | − | − | + | + | + | 5q33.2 | CD 168 | ||||||
| CD169 | Sialoadhesion/Siglec-1 | Adhesion structure | MUC1, CD206 | Mediates cell-cell, cell matrix interaction; may facilitate phagocytosis | 180/200 | + | + | 20p13 | CD169 | |||||||||
| CD170 | Siglec-5 | Adhesion structure | Terminal sialic acid residues | Adhesion molecule; as a pattern or self/non-self recognition receptor and mediates negative signals into the cell | 140 | + | + | + | 19q13.3 | CD170 | ||||||||
| CD171 | N-CAM, L1 | Adhesion structure | CD56, CD24 | Neuronal cell recognition molecule L1 involved in cell adhesion, cell spreading and motility. Also acts as a costimulatory molecule on lymphocytes | 200–230 | + | + | + | + | + | Xq28 | CD171 | ||||||
| CD172 | SIRP-1a | Adhesion structure | CD47 | Adhesion molecule; binds to CD47 and may mediate inhibitory signals via the ITIM/SHP-2 | 65 | + | + | + | + | 20p13 | CD172 | |||||||
| CD173 | Blood group H type 2 | Carbohydrate and lectin | Biosynthetic precursor of A and B antigen; carcinoma-associated antigen; may be involved in the homing process of hematopoietic stem cells to the bone marrow | − | + | + | + | CD173 | ||||||||||
| CD174 | Lewis Y | Carbohydrate and lectin | New hematopoietic progenitor cell marker; may be involved in the homing process of hematopoietic stem cells to the bone marrow | − | + | + | CD174 | |||||||||||
| CD175 | Tn | Carbohydrate and lectin | TFRA | Tumor-specific antigen expressed on various carcinomas; histo-blood group-related carbohydrate antigen; precursor of the blood groups ABO and TF antigen | − | − | − | + | + | CD175 | ||||||||
| CD175s | Sialyl-Tn (s-Tn) | Carbohydrate and lectin | TFRA | Tumor-specific antigen expressed on various carcinomas; histo-blood group-related carbohydrate antigen; precursor of the blood groups ABO and TF antigen | − | + | − | + | + | + | CD175s | |||||||
| CD176 | TF antigen | Carbohydrate and lectin | TFRA | Pan-carcinoma antigen tumor antigen marker; may be involved in metastasis of tumor cells | 120–198 | − | + | + | + | + | CD176 | |||||||
| CD177 | NB1, HNA-2a | Myeloid | NB antigens play a critical role in autoimmune neonatal neutropenia and autoimmune neutropenia; polymorphic; expressed in 89-97% of healthy individuals | 49–55/56–64 | + | CD177 | ||||||||||||
| CD178 | Fas ligand | CKR | CD95(Fas) | Involved in Fas/Fas ligand interaction, apoptosis, regulates immune responses, #Expressed on immature dendritic cells | 27–40/27–40 | ⊕ | − | +# | + | − | + | − | − | + | + | 1q23 | CD178 | |
| CD179a | VpreB | B | CD179b, μ heavy chain | Surrogate light chain VpreB is one of the components of the pre-B-cell receptor complex. #Expressed in cytoplasm of pro-B cells and on the surface of pre-B cells | 16–18/ | +# | 22q11.22 | CD179a | ||||||||||
| CD179b | λ5, 14.1 | B | CD179a, μ heavy chain | λ5 is one of the components of the pre-B-cell receptor complex.#Expressed in cytoplasm of pro-B cells and on the surface of pre-B cells | -/22 | +# | 22q11.23 | CD179b | ||||||||||
| CD180 | RP105/Bgp95 | B | LPS, MD-1 | May regulate the LPS signaling in B cells in concert with TLR4; ligation of CD180 induces proliferation of B cells and increases susceptibility to BCR-induced cell death | 95–105/95–105 | + | + | + | 5q12 | CD180 | ||||||||
| CD183 | CXCR3 | CK/CKR | IP-10, Mig, I-TAC | Involved with inflammation-associated effector T-cell chemotaxis | 40–41 | + | + | + | 8p12-p11.2, Xq13 | CD183 | ||||||||
| CD184 | CXCR4 | CK/CKR | HIV-1 | Homing receptor of hematopoietic progenitor cells; co-stimulation of B cells; induces apoptosis; involved with the entry of HIV-1 | + | + | + | + | + | + | + | − | + | + | 2q21 | CD184 | ||
| CD195 | CCR5 | CK/CKR | HIV-1 | Regulates lymphocyte chemotaxis activation and transendothelial migration during inflammation. Neutralizes HIV infection. #Expressed on immature dendritic cells | 37.0/40.6 | + | − | +# | − | + | + | − | − | − | CD195 | |||
| CDw197 | CCR7, EBI1, BLR2 | CK/CKR | SLC/6Ckine,ELC/MIP-3b | Lymphocytes and dendritic cell homing to lymphoid organs | 90 | + | + | + | + | + | + | – | – | 9p13 | CDw197 | |||
| CD200 | OX2 | Non-lineage | OX2R | Ig-SF, OX2 shares many biochemical similarities with Thy-1; may regulate myeloid cell activity | 40–45 | + | + | − | + | − | − | − | − | + | CD200 | |||
| CD201 | EPCR | Endothelial cells | Protein C | Involved in protein C activation | 49/25 | + | 20q11.2 | CD201 | ||||||||||
| CD202b | TEK/Tie2 | Endothelial cells | Angiopoietin-1,2, and 4 | Involved in vascular development | 140 | + | 9p21 | CD202b | ||||||||||
| CD203c | PDNP3, B10,PDIβ,E-NPP3 | Myeloid | Oligonucleotides | Multi-functional ectoenzyme involved in the clearance of extracellular nucleotides.#Expressed on basophils, mast cells, and their precursors | 270/130, 150 | +# | +# | 6q22 | CD203c | |||||||||
| CD204 | MSR | Myeloid | LDL | Role in deposition of cholesterol through receptor mediated uptake of LDL; recognition and elimination of pathogenic microorganisms | 220 | + | CD204 | |||||||||||
| CD205 | DEC-205 | Dendritic cell | Unknown | Antigen-uptake receptor for mannosylated antigens; present on both CD11c+ blood dendritic cells and in lesser density on surface of T and B cells | 198 | + | + | + | + | + | CD205 | |||||||
| CD206 | MMR | Dendritic cell | Sialodine sins and CD45 | Mediates endocytosis of glycoconjugates with terminal mannose, fucose N-acetylglucosamine or glucose residues | 162–175 | + | + | + | 10p13 | CD206 | ||||||||
| CD207 | Langerin | Dendritic cell | Found on a subset of cultured blood CD11c+ DC and TGF beta differentiated MoDC. Provides new reagent for characterizing Langerhans histiocytosis. Endocytic receptor with functional lectin domain with mannose specificity | + | + | + | 2p13 | CD207 | ||||||||||
| CD208 | DG-LAMP | Dendritic cell | Function unknown. Possible participation in peptide loading onto MHC class II | + | + | 3q26.3-q27 | CD208 | |||||||||||
| CD209 | DC-SIGN | Dendritic cell | Expressed on MoDC but not on blood DC even after activation; contributes to the initial adhesion interaction between MoDC and naïve T cells, regulation of T cell proliferation | 44 | − | − | + | 19p13 | CDw209 | |||||||||
| CDw210 | CK | CK/CKR | IL-10 | Receptors involved with cell signaling and immune regulation | 90 | − | + | − | 11q23.3, 21q22.11 | CDw210 | ||||||||
| CD212 | CK | CK/CKR | IL-12 | Tyrosine kinase membrane receptor for angiopoietin; involved in cell signaling and immune regulation | -/110 | ⊕ | − | + | − | − | 19p13.1 | CD212 | ||||||
| CD213a | CK | CK/CKR | IL-13 | Receptors involved in cell signaling and immune regulation. CD213a1, CD213a2 | − | − | − | + | − | + | x13 | CD213a | ||||||
| CDw217 | CK | CK/CKR | IL-17 | Involved in inflammation, osteogenesis, and granulopoiesis | + | + | + | + | 2p31 | CDw217 | ||||||||
| CD220 | Insulin R | Non-lineage | Insulin | Functions in the clearance of ligands rather than intracellular signaling | + | + | − | + | + | + | 19p13.3 | CD220 | ||||||
| CD221 | IGF1 R | Non-lineage | Insulin | Functions in the clearance of ligands rather than intracellular signaling | + | + | + | + | + | + | 15q25–26 | CD221 | ||||||
| CD222 | M6P/IGFII-R | Non-lineage | Plasminogen, M6P and IGFII | Plays role in the transport of newly synthesized acid hydrolases to lysomes | 250 | + | + | + | + | + | + | CD222 | ||||||
| CD223 | LAG-3 | Non-lineage | MHC class II | Cell activation Gene-3, like CD4, interacts with MHC class II molecules | 70 | ⊕ | − | − | ⊕ | + | − | − | 12p13 | CD223 | ||||
| CD224 | GGT | Non-lineage | GSH | G-glutamyl transderase; ectoenzyme; maintains intracellular glutathione (GHS) concentrations and consequently a state of oxidative homeostasis within cellular microenvironments | 27–68 | + | + | − | + | + | − | + | CD224 | |||||
| CD225 | Leu 13 | Non-lineage | IFN-γ | Interferon-inducible protein may play role in controlling cell-cell interactions | 17 | + | + | + | + | − | − | + | − | CD225 | ||||
| CD226 | DNAM-1, PTA1 | T | LFA-1 | Adhesion molecule; cytolytic function mediated by CTL and NK cells; platelet and T cell activation antigen 1 | 65 | + | + | + | + | + | − | + | − | − | 18q22.3 | CD226 | ||
| CD227 | MUC1 | Non-lineage | CD54, CD169 | Involved in cell surface protection and modulation of adhesion and cell migration | 300 | ⊕ | + | + | + | ⊕ | + | CD227 | ||||||
| CD228 | p97, gp95, MT | Non-lineage | GPI-anchored melanoma-associated protein | 97 | − | − | − | + | − | − | + | CD228 | ||||||
| CD229 | Ly9 | Non-lineage | SAP protein | In activated T cells, the SAP protein binds to and regulates signal transduction events initiated through the engagement of SLAM, 2B4, CD84, and Ly-9 | 100 | + | + | + | − | − | − | − | 1q22 | CD229 | ||||
| CD230 | Prion Protein (PrP) | Non-lineage | Isoform PrPsc (pathological) is present in transmissible spongiform encephalitis (TSE) | 33–37 | + | + | + | + | + | + | CD230 | |||||||
| CD231 | TALLA-1/A15, TALLA | Non-lineage | Highly expressed on T cell acute lymphoblastic leukemia; can be potentially useful as an anti-tumor agent | 30–45 | + | CD231 | ||||||||||||
| CD232 | VESP-R | Non-lineage | CD108 | Receptor for CD108 and semaphorin from virus; A39R (protein of semaphorin family) upregulates ICAM-1 and induces cytokine production | 200 | + | + | + | + | CD232 | ||||||||
| CD233 | Band 3/AE1 | RBC | Carrier of the Diego blood group system; maintains red cell morphology; Band 3 is essential for terminal erythroid differentiation | 95–105 | − | − | − | − | − | − | − | + | − | 17q12-q21 | CD233 | |||
| CD234 | DARC/Fy-glycoprotein | RBC | IL-8, MGSA RANTES, MCP-1 | Carrier of the Duffy blood group system; binds to a number of chemokines to modulate the intensity of inflammatory reactions | 34–43 | − | − | − | − | + | − | − | − | + | + | + | 1q22–23 | CD234 |
| CD235a | Glycophorin A | RBC | Major membrane sialoglycoprotein of RBC membrane and carrier of blood group M and N specificites | − | − | − | − | − | − | − | − | + | − | 4q28-q31 | CD235a | |||
| CD235ab | Glycophorin A and B | RBC | Glycophorin B is the carrier of blood group S, s, and N specificities (for Glycophorin A see CD235a) | − | − | − | − | − | − | − | − | + | − | − | 4q28-q31 | CD235ab | ||
| CD236 | Glycophorin C and D | RBC | One of the chored protein of red blood cell skeleton that maintains cell morphology; carrier of Gerbich blood group | 30–40 | + | + | 2q14-q21 | CD236 | ||||||||||
| CD236R | GlycophorinC, GYPC | RBC | Plays a role in the invasion and intra-erythrocytic development of P. falciparum | 40 | + | 2q14-q21 | CD236R | |||||||||||
| CD238 | Kell | RBC | Endothelin-3 | Kell is classified as a member of the small neprilysin (M13) family of zinc metalloproteases, which include CD10. Kell antibodies inhibit erythropoeisis | 93 | + | 7q33 | CD238 | ||||||||||
| CD239 | Lu/B-CAM | RBC | Laminin | Carrier of the Lutheran blood group; receptor for laminin; plays role in terminal erythroid differentation; facilitates trafficking of more mature RBC | 78–85 | + | + | + | 19q13.2 | CD239 | ||||||||
| CD240 | RBC | CD240 includes CD240CE (RhCE), CD240D (RhD), and CD240DCE (RhD/RhCE). Rh system is one of the most polymorphic in the blood group system comprising 45 different antigens; Rh antigen may promote export of ammonium | 30 | + | 1p34.3-p36.1 | CD240 | ||||||||||||
| CD241 | RhAG/Rh50 | RBC | Promotes export of ammonium that accumulates within erythrocytes; promotes erythrocyte-mediated retention of ammonium from the plasma and its release to detoxifying organs | 50 | − | − | − | − | − | − | − | − | + | 6p11-p21.1 | CD241 | |||
| CD242 | ICAM-4/LW | RBC | LFA-1, Mac-1, VLA-4 | Carrier of LW blood group system; involved in red cell senescence; interaction with VLA-4 may stabilize erythroblastic islands in normal BM | 37–43 | − | − | − | − | + | − | − | − | + | + | 19p13.3 | CD242 | |
| CD243 | MDR-1 | Sterm/progenitor cells | p-glycoprotein, drug resistance pump | 180 | − | − | − | + | − | − | − | − | CD243 | |||||
| CD244 | 2B4, P38, NAIL | NK | CD48 | Engagement of 2B4 with its ligand, CD48, or with specific antibodies enhances NK cell cytokine production and cytolytic function. #Found only on basophils | 70/70 | + | + | + | +# | 1q22 | CD244 | |||||||
| CD245 | p220/240 | T | Lymphocyte receptor | Signal transduction and co-stimulation of T and NK cells; function is distinct from CD45 or CD148 | 220–250 | + | + | + | + | + | − | CD245 | ||||||
| CD246 | ALK | T | Tyrosine kinase R | Expressed in T cell lymphoma subtype; suggested role in cellular proliferation, apoptosis and embryonic neural differentiation | 200 | + | 2p23 | CD246 | ||||||||||
| CD247 | Zeta chain | T | Essential signal sub-unit of activating receptor on T and NK cells | + | + | 2p23 | CD247 | |||||||||||
Key:
- +
- Positive
- ⊕
- Positive upon activation
- +c
- Positive by cytoplasm staining
- -
- Negative
- +#
- Refer to ‘Description and function’ column for further details
- *
- A CD nomenclature of detailing LIR/ILT genes (CD85) as well as KIR genes (CD158) has been proposed based on the previous
- †
- CD designation of some members of this family and on the position of the genes on chromosomes 19q13.4 from centromeric to telomeric loci
Abbreviations::
- MW
- Molecular weight is shown as non-reduced/reduces where available
- CK/CKR
- Cytokine/chemokine receptors